Strategic licensing partnership brings fresh capital while narrowing the company’s focus on therapies targeting the biology of aging.
A $35 million deal may not sound unusual in biotech, but for regenerative medicine company Celularity, the agreement announced this week is less about cashing in and more about clearing the runway for a deeper bet on longevity science [1].
The New Jersey-based company has entered a strategic licensing partnership for its placental-derived biomaterials portfolio, a move expected to bring in upfront payments and milestone-based funding totaling up to $35 million. The transaction is slated to close no later than 15 April, 2026, pending customary conditions.
At its core is a strategic trade. Celularity is handing off commercialization rights to a set of products while holding on to something equally important – the ability to manufacture them. That decision allows the company to keep a revenue stream flowing while shifting more of its energy toward therapies designed to address the underlying biology of aging. Celularity is reorganizing itself around the long game.
Under the agreement, Celularity granted an exclusive license covering its commercial-stage biomaterials portfolio along with certain development-stage programs. In return, the company expects to receive upfront funding and potential milestone payments totaling up to $35 million.
Crucially, the funding is non-dilutive, meaning the company does not have to issue new shares or give up more ownership to secure the capital.
But Celularity did not fully step away from the business it is licensing out. Instead, the company will remain the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey. That means even as another partner handles commercialization, Celularity will continue producing the products and may also earn royalties if development-stage therapies reach the market.
It is a structure that reflects a broader trend in biotech: companies are increasingly monetizing parts of their portfolio to fund the more ambitious (and expensive) work of developing next-generation therapies.
Alongside the licensing deal, Celularity is undergoing an internal realignment to reduce operating costs and more tightly focus resources on longevity-focused research.
Personnel associated with commercial biomaterials activities are expected to transition to the partner company upon the deal’s closing. Additional workforce reductions will follow as part of the restructuring.
For a company working at the intersection of regenerative medicine and aging research, the move signals a shift toward specialization. Longevity biotechnology is still an emerging field, and advancing therapies that target aging itself, rather than just the diseases that follow it, requires significant investment and long development timelines. Streamlining the organization, then, becomes part of the strategy.
Why researchers are looking to the placenta
Celularity’s science revolves around an unlikely biological resource: the postpartum placenta. Normally discarded after birth, the placenta contains a rich mix of cells and biological materials that scientists believe may help regulate immune responses and support tissue repair. Those properties have sparked growing interest among researchers developing regenerative therapies.
The placenta acts as a biological mediator during pregnancy, balancing the immune system and supporting rapid tissue growth. Scientists believe those same capabilities could potentially be harnessed to address some of the biological changes associated with aging.
Celularity’s research programs focus on therapies derived from placental cells that aim to address processes linked to aging, including cellular senescence, chronic inflammation and tissue degeneration. These mechanisms are widely recognized by scientists as key drivers of aging and many age-related diseases.
Targeting them could have ripple effects across multiple conditions, from degenerative disorders to chronic inflammation.
A strategic bet on longevity medicine
For Celularity’s leadership, the deal is as much about focus as it is about financing. Dr Robert J Hariri, the chairman and CEO, said that the partnership served as a strategic move to bolster their capital and refine their focus on longevity medicine. He further noted that Celularity’s proprietary placental technology offers distinct biological benefits within that field.
“We are monetizing commercial infrastructure in a capital-efficient manner, reducing operating complexity, and retaining long-term economic participation through manufacturing and royalties. This transaction enhances our ability to concentrate resources on high-value cellular therapeutics targeting the fundamental mechanisms of aging,” he added.
The company also signaled plans to expand clinical and commercial opportunities in jurisdictions where investigational use of biologic technologies may be permitted under state frameworks, including Florida, Texas and Arizona.
Such pathways remain carefully regulated, but they represent an evolving landscape in which scientists and physicians are exploring new ways to study regenerative therapies.
Longevity’s growing strategic shift
Seen in isolation, Celularity’s deal is a corporate restructuring story, but in the context of the broader longevity sector, it reflects that companies across the space are increasingly reorganizing themselves around the biology of aging itself, the cellular processes that slowly accumulate damage over time.
Instead of targeting diseases one by one, the emerging strategy is to intervene earlier in the biological chain of events. If successful, therapies addressing those root mechanisms could influence multiple age-related conditions simultaneously.
That vision remains scientifically ambitious and commercially uncertain. But moves like Celularity’s licensing deal show how companies are beginning to restructure their business models around it.
READ MORE: Overcoming the ‘perfect storm’ in regenerative medicine
